CHARLOTTESVILLE, Virginia, December 17 /PRNewswire/ — Biovista Inc. today announced the signing of a contract with Novus Biologicals for access to Biovista’s BEA literature mining platform. BEA will be used to power Novus Explorer, a new service that Novus Biologicals is offering to visitors of its web site. Driven by BEA, Novus Explorer will allow site visitors to identify genes that are related to proteins, pathways and diseases of interest to them, and from these browse Novus reagents that have been reported in the literature to work well in experiments with those genes.
“We are very pleased that Novus selected our BEA platform to drive this exciting new service,” said Aris Persidis, Ph.D., President of Biovista. “The flexibility of our BEA platform has allowed us to put together in a relatively short amount of time this custom solution which meets Novus’ criteria for useful information provision coupled with specifics from Novus’ own line of products”, Dr Persidis added.
“Novus is glad to have selected Biovista’s proven technology to support a service we hope will be of use to our site visitors and existing customers”, said Karen Padgett, CEO of Novus. “With Novus Explorer we aim to offer a free service that will help researchers better understand their problem space and at the same time enhance the user experience of our site visitors. Biovista’s BEA platform was a solution we found quite promising and we will be looking forward to our visitors comments,” Karen added.
About Biovista and the BEA platform
Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista’s proprietary repositioning technology allows the company’s experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and very short time spans. The BEA platform is a literature mining solution that allows researchers to search scientific literature in ways that support scientific discovery in a systematic way.
For more information, please contact:
Dr. Aris Persidis, President